ESC Presentation for HART PAD

Performance of Clinical/Proteomic panel to predict obstructive peripheral artery disease in patients with and without diabetes mellitus

European Society of Cardiology (ESC) Scientific Sessions, Munich, Germany

August 25, 2018

Highlights & Key Findings

  • Peripheral artery disease (PAD) is a global health problem associated with significant morbidity and mortality. Patients with diabetes mellitus (DM) are at substantial risk of developing PAD, however its diagnosis is often delayed until advanced stages when complications arise.

  • PAD affects more than 202 million people worldwide and is often underdiagnosed and undertreated until the disease has reached advanced stages. Patients with DM are at substantial risk of developing PAD. Patients with PAD have increased risk of coronary artery disease (CAD), heart attack, or stroke, and, if left untreated, PAD can lead to foot or leg amputation.

  • Using proteomics and machine learning (a subset of artificial intelligence), a biomarker clinical/proteomic panel was validated to predict prevalent obstructive PAD (HART PAD) in patients undergoing diagnostic peripheral angiography and/or coronary angiography.

  • The clinical/proteomic HART PAD panel consists of one clinical variable (history of hypertension) and concentrations of six biomarkers (midkine, kidney injury molecule-1, interleukin-23, follicle stimulating hormone, angiopoietin-1, and eotaxin-1).

  • In a prospective cohort of 354 patients referred for diagnostic peripheral angiography and/or coronary angiography enrolled in the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study (Clinical Trials.Gov NCT00842868), performance of this diagnostic panel was assessed in patients with (N=94) and without DM (N=260) using Monte Carlo cross validation.

  • In patients with DM, the HART PAD panel had excellent performance for diagnosis of PAD. Using a 5- point score, a score of 1 had a 100% Negative Predictive Value (NPV) and a score of 5 had a 95% Positive Predictive Value (PPV). Additionally, the HART PAD panel was highly accurate in predicting the need for revascularization in patients with PAD. These results were comparable to those patients without DM.

Conclusions

  • In a prospective cohort study, we describe a clinical/ biomarker score with high accuracy for predicting the presence of PAD and need for revascularization in patients with and without DM.

Scroll Down for the ESC Presentation for HART PAD

The 2018 ESC Presentation for HART PAD